Trastuzumab - Globe Thesis

Keyword [Trastuzumab] Result: 81 - 100 \| Page: 5 of 8
81.	The HER4-YAP1 Axis Promotes Trastuzumab Resistance In HER2 Positive Gastric Cancer By Inducing EMT Transition
82.	Long Non-coding RNA-UCA1 Desensitizes Breast Cancer Cells To Trastuzumab By Impeding MiR-18a Repression Of Yes-associated Protein 1
83.	The Role And Mechanism Of EPHA5 In The Trastuzumab Resistance Of HER2-positive Breast Cancer
84.	Optimized Metformin And Trastuzumab Dosing Schedule Based On Circadian Dynamics Of Glucose Metabolism Overcome Trastuzumab Resistance In HER2-positive Gastric Cancer
85.	The Mechanism Of Trastuzumab Resistance In Breast Carcinomas With HER-2 Mutation Factors Influencing Non-sentinel Lymph Nodes Metastases Of Breast Cancer And Implications For Treatment
86.	Research Of Novel Skin Toxicities Of Anti-PD-1 Treatment And Mechanism Of Resistance To Anti-HER2 Treatment For Advanced Solid Tumors
87.	Construction Of Cucurmosin-based Immunotoxin Targeting HER-2 With Potent In Vitro Anti-cancer Cytotoxicity
88.	Membrane Cholesterol Decreased Chemotherapy Sensitivity In HER2-positive Trastuzumab Resistant Gastric Cancer Via Upregulation Of ABCB1
89.	The Predictive Value Of Tils For Trastuzumab In Her-2 Positive Breast Cancer
90.	The Study About The Effect Of Postoperative Adjuvant Therapy On Cancer Treatment-related Cardiac Dysfunction In Breast Cancer Patients
91.	Involvement Of ER Stress In Mechanism Of Trastuzumab Resistance Occurrence And Transmission Of HER2-positive Gastric Cancer
92.	SP1 Promotes Tumor Aniogenesis And Invasion By Activating VEGF Expression In Acquired Trastuzumab-resistant Ovarian Cancer Model
93.	HER2 Positive Bilateral Metachronous Primary Breast Carcinoma: A Case Report And Literature Review
94.	RBM38 Induces Tarstuzumab Sensitivity In HER-2 Positive Breast Cancer By Increasing The Expression Of HER-2
95.	Study On The Mechanism Underlying Valproic Acid Reversed Trastuzumab Resistance In HER2-positive Breast Cancer Cells
96.	The Analysis Of Diagnosis And Treatment In HER2 Positive Breast Cancer
97.	Cardiotoxic Analysis Of Trastuzumab Treatment In Her-2 Positive Breast Cancer Patients
98.	An Observational Study Of Immune Function Status In Patients With HER-2 Positive Early Breast Cancer Treated With Chemotherapy Combined With Trastuzumab
99.	The Cardiotoxicity Risks Of Anthracycline And Trastuzumab In HER-2 Positive Breast Cancer Patients
100.	Effect Of Neoadjuvant In Combination With Chemotherapy On Tumor-infiltrating Lymphocytes And PD-L1 Expression In HER2-overexpression Breast Cancer And Its Clinical Significance
<<First <Prev Next> Last>> Jump to